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Oil palm (Elaeis guineensis) leaves extract (OPLE) has antioxidant properties and because oxidative stress contributes to the
pathogenesis of diabetic nephropathy (DN), we tested the hypothesis that OPLE prevents diabetes renal oxidative stress,
attenuating injury. Sprague-Dawley rats received OPLE (200 and 500mg kg−1) for 4 and 12 weeks after diabetes induction
(streptozotocin 60mg kg−1). Blood glucose level, body and kidney weights, urine flow rate (UFR), glomerular filtration rate
(GFR), and proteinuria were assessed. Oxidative stress variables such as 8-hydroxy-2′-deoxyguanosine (8-OHdG), glutathione
(GSH), and lipid peroxides (LPO) were quantified. Renal morphology was analysed, and plasma transforming growth factor-beta1
(TGF-β1) was measured. Diabetic rats demonstrated increase in blood glucose and decreased body and increased kidney weights.
Renal dysfunction (proteinuria, elevations in UFR and GFR) was observed in association with increases in LPO, 8-OHdG, and
TGF-β1 and a decrease in GSH. Histological evaluation of diabetic kidney demonstrated glomerulosclerosis and tubulointerstitial
fibrosis. OPLE attenuated renal dysfunction, improved oxidative stress markers, and reduced renal pathology in diabetic animals.
These results suggest OPLE improves renal dysfunction and pathology in diabetes by reducing oxidative stress; furthermore, the
protective eﬀect of OPLE against renal damage in diabetes depends on the dose of OPLE as well as progression of DN.
1. Introduction
Diabetic nephropathy (DN) is a major microvascular com-
plication of diabetes and is the leading cause of chronic
renal failure and end-stage renal disease (ESRD) worldwide.
Traditionally, DN has been described as a glomerular
disease with the following stages: glomerular hyperfiltration,
incipient nephropathy, microalbuminuria, overt proteinuria,
and ESRD [1]. The morphological changes that occur in DN
include glomerular hypertrophy, thickening of glomerular
basement membrane, and mesangial expansion. These mor-
phological changes probably give rise to proteinuria, renal
dysfunction, and eventually to development of glomeru-
losclerosis and tubulointerstitial fibrosis [2]. At present no
adequate treatment is available for diabetic renal injury
[3–7] and thus other agents that can aﬀect the molecular
mechanisms which contribute to the pathogenesis of DN are
essential.
Studies in both humans and animal models clearly impli-
cate the contribution of oxidative stress to the pathogenesis
of DN [8–11]. Chronic hyperglycaemia is probably the
most important factor in the generation of oxidative stress.
Oxidative stress has an important role in the pathogenesis
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of glomerular and tubular function and structural abnor-
malities, these alterations include extracellularmatrix (ECM)
deposition in the mesangium, promotion of a hypoxic
environment via microvascular damage, induction of cellular
oxidant injury and, ultimately, promotion of tubulointer-
stitial fibrosis by activation of transforming growth factor
β1 (TGF-β1) [11–15]. In view of the potential hazards of
sustained hyperglycaemic-induced oxidative stress to the
kidney, a potent novel antioxidant to treat DN would be
highly desirable.
Treatments with antioxidants such as green tea and
antioxidant vitamins have however produced marginal
benefit in preventing the progression of diabetic renal
complications [16] and human studies have shown that
high doses of vitamin E failed to impart positive eﬀect
[17, 18]. The outcomes of these studies thus lay emphasis
on the significance of developing better novel antioxidant
treatments for reducing the incidence and attenuating the
progression of diabetic complications such as DN.
Oil palm (Elaeis guineensis) leaves are abundant, under-
utilised, by-products of the palm oil industry in tropical
countries including Indonesia, Thailand, Malaysia, Africa,
and South America, and the oil palm leaves have been used
for decades as ruminant feed without any reports of toxicity.
The methanol extract of these leaves is rich in flavonoids and
catechins [19]; catechins are polyphenolic compounds which
possess antioxidant activity that is several folds higher than
that of vitamins C and E. Indeed the antioxidant properties
of oil palm leaves extract (OPLE) which is rich in these
compounds have been documented [20, 21].
The aim of the present study was therefore to investigate
the eﬀectiveness of OPLE in attenuating hyperglycaemia-
mediated oxidative stress and renal dysfunction in
streptozotocin-induced diabetic rats. Impact of this
treatment on metabolic parameters and renal function was
determined. In addition, morphologic change was observed
in renal tissues and oxidative stress markers (8-hydroxy-
2′-deoxyguanosine, lipid peroxides, and glutathione) were
measured in urine and renal tissues. TGF-β1, a key mediator
of ECM accumulation in diabetic kidney, was measured in
plasma.
2. Materials and Methods
2.1. Chemicals. Standardised OPLE was obtained from Nova
Laboratories, Malaysia (Batch no: WH 1446). Streptozotocin
(STZ) was purchased from Sigma-Aldrich (St. Louis, MO,
USA). Enzyme-linked immunosorbent assay for the deter-
mination of glutathione (GSH), lipid peroxides (LPO), and
8-hydroxy-2′-deoxyguanosine (8-OHdG) was obtained from
Cayman Chemicals (Ann Arbor, MI, USA). Enzyme-linked
immunosorbent assay for the determination of transforming
growth factor-beta 1 (TGF-β1) was obtained from Abnova
(Walnut, USA). Other standard chemicals were obtained
from common commercial suppliers.
2.2. Preparation of OPLE. Ethanolic fraction of oil palm
leaves was prepared as described by the manufacturer:
briefly 50 g of dried oil palm leaves was macerated with
500mL of water and ethanol (3 : 7 v/v) at about 60–65◦C for
approximately 60min was filtered. The extract was applied
to column adsorptive chromatography (Amberlite XAD 16
HP, Rohm & Haas) and eluted with water: isopropanol (3 : 7
v/v) with a constant flow rate of 25mLmin−1, at 60◦C and
a pressure of 0.5–1 bar. The eluant was concentrated in a
rotary evaporator and dried in a vacuum oven at 60◦C for
8 h to yield a 2.5 g yellow-beige powder. The powder extract
was stored in a refrigerator at 2–8◦C for use in subsequent
experiments. Preliminary screening revealed the presence
of 1.1% (−) catechin gallate and 1.5% ferulic acid in the
powder extract.
2.3. Experimental Animals and General Preparations. All
experimental procedures were approved and complied
with the Guidelines for the Care and Use of Labora-
tory Animals at University of Malaya in Kuala Lumpur
(FAR/20101106/NAA-R). Male Sprague-Dawley rats weigh-
ing 270–330 g were acclimatized for 1 week before starting
any experiment. They were kept under controlled conditions
with a 12 h light: dark cycle and at 21–25◦C. All rats were
allowed unrestricted access to standard rat pellet and tap
water. Animals were randomly divided into four groups
(n = 10 to 15 per group), namely, nondiabetic (N), diabetes
control group (D), diabetes group treated with OPLE at a
dose of 200mg kg−1 and 500mg kg−1, respectively. A single
intraperitoneal (i.p.) injection of STZ at a dose of 60mg
kg−1 was used to induce diabetes. STZ was dissolved in
freshly prepared 0.9% sodium chloride (pH 4.5). Control rats
received an equal volume of saline by i.p. injection. Diabetes
was confirmed after 72 h by measuring blood glucose levels
with the use of glucose oxidase reagent strips (one touch
glucometer, Accu Chek). Rats with a blood glucose level of
>12mmol L−1 were selected for the study. After confirmation
of diabetes, the rats were treated with OPLE orally by gavage
daily for 4 and 12 weeks. Age-matched nondiabetic and
diabetic control groups did not receive any treatment. Blood
glucose levels were measured twice in a week. After 4 weeks,
the percentages of survivors amongst the diabetic groups
were 80%, 80% and 90% in each group, respectively. The
percentages of survivors 12 weeks after diabetes induction
were 70%, 75%, and 80% in each group, respectively. At the
end of the 4 and 12 week periods, the rats were anaesthetised
with sodium pentobarbital (60mg kg−1, i.p.) for the acute
study to examine evidence of renal dysfunction and injury.
2.4. Surgical Preparation and Functional Studies. A tra-
cheostomy was performed to facilitate respiration. The left
jugular vein and carotid artery were cannulated for anaes-
thetic infusion (12.5mg kg−1 h−1 at 3mL h−1 in 140mM
NaCl) and arterial pressure recordings (Power Lab Systems
and pressure transducer, AD Instruments), respectively while
the left femoral artery was cannulated for blood sample
collections. The left kidney was exposed via a flank incision
and a catheter was placed in the urinary bladder for urine
collections. An electromagnetic flow probe was placed on
the renal artery for renal blood flow (RBF) measurement
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(Carolina Square-wave Electromagnetic flowmeter and EP
100 series probe; Carolina Medical, NC, USA). Inulin
(10mgmL−1) was included in the infusate. Thereafter, a
2mL priming dose solution (10mgmL−1 inulin in 140mM
NaCl) was administered to the rat via the jugular vein.
Following a 1 h equilibration period, four 30min clearances
were taken. Arterial blood samples were taken at the
beginning and at the end of every two clearances. The blood
samples were centrifuged and plasma was frozen at −20◦C
for subsequent analysis. At the end of the study, the rat
was killed by a rapid intravenous injection of 1mL sodium
pentobarbital and the right kidney was harvested, dissected
into cortex and medulla, and snap frozen in liquid nitrogen
for measurement of GSH and LPO. The left kidney was
perfused first with ice-cold phosphate buﬀered saline until
cleared of blood and then fixed with 10% formalin for
histological evaluation.
2.5. Biochemical Analysis. Urinary protein concentrations
were determined by biuret reagent, according to the method
developed by Doumas et al. [22]. Urine and plasma
electrolytes (sodium and potassium) concentrations were
analysed using a flame photometer (Sherwood, Model 420,
UK) and urine volume was measured gravimetrically. Inulin
content in urine and plasma samples was determined accord-
ing to the method of Somogyi [23] after the samples were
deproteinized according to the method proposed by Bojesen
[24]. Glomerular filtration rate (GFR) was equated with
renal clearance of inulin and was expressed as mLmin−1 g−1
kidney weight.
2.6. Reduced GSH in Kidney. Cytosolic reduced GSH in renal
cortex homogenates was measured using a glutathione assay
kit from Cayman Chemicals according to the manufacturer’s
protocol. The sample (100–150 μg) is deproteinized using
metaphosphoric acid, and the amount of the yellow coloured
5-thio-2-nitrobenzoic acid produced in the supernatant was
measured at 410 nm.
2.7. LPO in Kidney. LPO in the renal cortex was measured
colourimetrically using a Cayman’s assay kit. Briefly, renal
cortex was homogenized in HPLC-grade water and LPO
was extracted from the homogenates according to the
manufacturer’s protocol. LPO was measured directly by
redox reactions with ferrous ions using the kit, and the
resulting ferric ions were detected using thiocyanate ion as
the chromogen.
2.8. Urinary Excretion of 8-OHdG. 8-OHdG is one of the
most common markers for oxidative DNA damage and
oxidative stress in vivo. ELISA kit from Cayman Chemicals
was used to measure 8-OHdG levels in 2 h urine samples.
The 8-OHdG standards (0.5–80 ngmL−1) or 35–50 μL of
urine were allowed to incubate for 1 h with monoclonal
antibody against 8-OHdG in a microtiter plate precoated
with 8-OHdG. After washing the antibodies bound to 8-
OHdG in the sample, enzyme-labelled secondary antibody
was added to each well and incubated for 1 h followed
by washing. The colour that developed by the addition of
3,3′,5,5′-tetramethylbenzidine was measured by absorbance
at 450 nm. Urinary 8-OHdG was expressed as total amount
excreted in 2 h.
2.9. Plasma TGF-β1. Plasma samples were collected from the
experimental animals on the 4th and 12th weeks. Samples
were frozen at −20◦C until analysis. ELISA kit was used
to measure plasma TGF-β1 concentration according to
manufacturer’s protocol. Each 50 μL of plasma sample was
first acid activated by incubation with 1 μL of 1.0N HCl
for 15min at room temperature and neutralized by 1 μL of
1N NaOH for the activation of the plasma TGF-β1 to the
immunoreactive form. Plasma TGF-β1 is expressed as total
amount excreted in pgmL−1.
2.10. Morphologic Study. After formalin fixation, renal tis-
sues were embedded in paraﬃn. Tissue sections were cut
at 5 μm thickness using a microtome, dewaxed, and stained
with periodic acid-Schiﬀ (PAS) and Masson’s trichrome.
Renal morphology changes within the glomeruli and inter-
stitial areas were assessed with the aid of a Nikon Eclipse 80i
light microscope, using a semiquantitative scoring method
[25, 26].
2.11. Statistical Analysis. Data are shown as mean ± SEM.
The mean values were compared among the 4 groups using
one way analysis of variance (ANOVA), followed by Tukey
Multiple Comparison Test (Graph Pad Prism). Experimental
diﬀerences were considered statistically significantif P < 0.05.
3. Results
3.1. Metabolic Parameters. Table 1 shows the eﬀects on the
changes in body and kidney weights of diabetic rats after
oral administration of 200mg kg−1 and 500mg kg−1 OPLE.
The mean body weight in diabetic rats was 1.2-fold and 1.8-
fold lower than in nondiabetic rats at 4 and 12 weeks after
induction of diabetes, respectively; however, the diﬀerence
was only significant at 12 weeks (P < 0.001). In contrast,
kidney weight normalised by 100 g body weight in diabetic
group was significantly heavier than in nondiabetic rats by
1.4-fold (P < 0.01) and 2.2-fold (P < 0.001) at 4 and
12 weeks of diabetes, respectively. OPLE did not aﬀect the
mean body weight or kidney to body weight ratio in diabetic
rats at the doses tested for both the 4-week and 12-week
experimental duration. Even though the diﬀerence is not
statistically significant, OPLE at 500mg kg−1showed a slight
tendency to reduce renal enlargement in rats with 12 weeks
diabetes.
STZ-induced diabetes demonstrated a tremendous ele-
vation of blood glucose level in all the diabetic groups,
random glucose levels in the whole blood of diabetic rats, and
diabetic rats treated with OPLE at 200mg kg−1 and 500mg
kg−1 were significantly higher than that of nondiabetic rats
(6.5-, 6.8- and 6.6-fold, respectively, all P < 0.001) at 4
weeks after induction of diabetes. Similarly, 12 weeks after
the induction of diabetes, random blood glucose level was
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Table 1: Eﬀects of OPLE on body and kidney weights, random blood glucose level, and mean arterial pressure.
Nondiabetic Diabetic control
Diabetic + OPLE Diabetic + OPLE
200mg kg−1 500mg kg−1
(4 week) (4 week) (4 week) (4 week)
(12 week) (12 week) (12 week) (12 week)
Body weight g
365.0 ± 14.3 309.2 ± 25.4 303.3 ± 37.6 283.3 ± 17.2
428.3 ± 13.0 235.0 ± 14.6aaa 251.7 ± 17.2aaa 289.2 ± 14.9aaa
Kidney weight g 100 g−1 body weight
0.40 ± 0.01 0.57 ± 0.03aa 0.53 ± 0.04a 0.59 ± 0.04aa
0.32 ± 0.02 0.69 ± 0.02aaa 0.62 ± 0.04aaa 0.59 ± 0.02aaa
Glucose level mmol L−1
4.7 ± 0.1 30.7 ± 1.7aaa 32.2 ± 0.5aaa 31.2 ± 2.1aaa
6.3 ± 0.2 31.0 ± 1.2aaa 31.6 ± 1.1aaa 33.1 ± 0.2aaa
Mean arterial pressure mmHg
113.2 ± 2.1 115.3 ± 3.2 109.3 ± 3.7 116.7 ± 1.9
111.5 ± 2.9 116.7 ± 3.3 109.0 ± 5.3 112.2 ± 3.9
Data are expressed as mean ± SEM of six experiments for each group. aP < 0.05; aaP < 0.01; aaaP < 0.001 versus corresponding nondiabetic.
Table 2: Eﬀect of OPLE on renal functional parameters.
Nondiabetic Diabetic control
Diabetic + OPLE Diabetic + OPLE
200mg kg−1 500mg kg−1
(4 week) (4 week) (4 week) (4 week)
(12 week) (12 week) (12 week) (12 week)
Renal blood flow mLmin−1 g−1 kidney
1.43 ± 0.10 2.27 ± 0.39 1.72 ± 0.26 1.80 ± 0.03
1.66 ± 0.14 2.49 ± 0.16aaa 1.78 ± 0.06bb 1.47 ± 0.05bbb
Glomerular filtration rate mLmin−1 g−1 kidney
0.61 ± 0.06 0.96 ± 0.04aa 0.67 ± 0.07b 0.63 ± 0.09b
0.50 ± 0.05 0.84 ± 0.06aa 0.75 ± 0.06a 0.58 ± 0.02b
Urine flow rate μLmin−1 g−1 kidney
3.75 ± 0.59 10.68 ± 1.30aaa 5.27 ± 0.45bb 5.80 ± 0.80bb
2.89 ± 0.34 7.84 ± 0.70aaa 6.42 ± 0.50aa 5.29 ± 0.70a,b
Urinary protein excretion mg 2 h−1
1.33 ± 0.03 6.83 ± 0.30aaa 2.87 ± 0.17a,bbb 1.89 ± 0.34bbb
1.13 ± 0.05 4.66 ± 0.73aaa 2.92 ± 0 .26a,b 2.68 ± 0.21a,bb
Fractional sodium excretion %
0.63 ± 0.19 1.34 ± 0.34 0.96 ± 0.22 0.90 ± 0.17
0.56 ± 0.08 1.08 ± 0.23 0.76 ± 0.24 0.79 ± 0.23
Data are expressed as mean ± SEM of six experiments for each group. aP < 0.05; aaP < 0.01; aaaP < 0.001 versus corresponding nondiabetic; bP < 0.05; bbP <
0.01; bbbP < 0.001 versus corresponding diabetic control.
significantly higher in all the diabetic groups compared to
that of nondiabetic group (all P < 0.001). Treatment of
diabetic animals with OPLE at the doses tested for 4 and 12
weeks did not aﬀect random blood glucose level (Table 1).
Mean arterial pressure was comparable between the four
study groups (Table 1) at 4 and 12 weeks.
3.2. Renal Haemodynamic. Renal blood flow (RBF) of var-
ious groups in the present study is listed in Table 2. RBF
did not diﬀer among the four study groups at 4 weeks.
Conversely, RBF was significantly increased in diabetic rats
compared with nondiabetic rats at 12 weeks (1.5-fold, P <
0.001). The increase in RBF was normalised by treatment
with 200mg−1 kg−1 and 500mg−1 kg−1 OPLE (P < 0.01 and
P < 0.001, resp.).
It is well established that early stages of DN are associated
with increases in glomerular filtration rate (GFR), both
clinically and experimentally. Rats with 4-week diabetes
in the present study exhibited elevated values for GFR
compared with those found in nondiabetic rats (1.6-fold,
P < 0.01), as evaluated by inulin clearance (Table 2).
Hyperfiltration was prevented by treatment with OPLE at
200mg kg−1 and 500mg kg−1 (both P < 0.05). These results
indicate that the rise in RBF may be responsible for the
hyperfiltration in diabetic rats, although a rise in glomerular
capillary pressure might also contribute.
Likewise, GFR was significantly greater (1.7-fold, P <
0.01) in rats of 12-week diabetes than in nondiabetic rats but
only the higher dose of OPLE (500mg kg−1) suppressed the
increase in GFR in diabetic rats (P < 0.05).
3.3. Renal Excretory Function. Untreated diabetic rats were
polyuric (Table 2); urine flow rate (UFR) increased remark-
ably in diabetic rats when compared to that of nondiabetic
rats at both 4 weeks (2.8-fold, P < 0.001) and 12 weeks
(2.7-fold, P < 0.001). This event may be the outcome of
hyperfiltration. Treatment with OPLE at both the concentra-
tions tested almost prevented the rise in urine flow rate at
4 weeks (both P < 0.01) but only the higher dose of OPLE
ameliorated the elevation in urine flow rate in diabetic rats
at 12 weeks (P < 0.05).
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To substantiate the beneficial eﬀect of OPLE treatment on
renal dysfunction in diabetes, we measured urinary protein
excretion in the four study groups (Table 2). Urinary protein
excretion increased significantly in diabetic rats compared
with nondiabetic rats at both 4 weeks (5.1-fold, P < 0.001)
and 12 weeks (4.1-fold, P < 0.001), indicating a modification
in glomerular barrier characteristics. Proteinuria induced by
diabetes was significantly reduced by treatment with OPLE
at both concentrations tested at 4 weeks (both P < 0.001);
furthermore, the higher dose reduced the excretion to almost
nondiabetic value. At 12 weeks, OPLE at both concentrations
tested ameliorated the increase in urinary protein excretion
in diabetic rats (P < 0.05 for 200mg kg−1 and P < 0.01 for
500mg kg−1). This finding shows that treatment with OPLE
prevents the development of proteinuria, a hallmark of DN,
in early diabetes.
We evaluated fractional sodium excretion to obtain
some information on the integrity of tubular reabsorptive
function. Our results showed fractional sodium excretion did
not diﬀer among the four experimental groups at both 4 and
12 weeks (Table 2).
3.4. Parameters of Oxidative Stress. In this study, we did
not quantify reactive oxygen species (ROS) directly but
alternatively measured the formation of oxidative damage
products or endogenous end-products of ROS to address the
eﬀect of OPLE on STZ-diabetes induced oxidative stress.
3.4.1. 8-Hydroxy-2-deoxyguanosine (8-OHdG). We exam-
ined the oxidative DNA damage in kidney of STZ-induced
diabetic rats by measuring the levels of 8-OHdG in urine
samples. The levels of urinary 8-OHdG (Figure 1) were
significantly greater in diabetic rats than in nondiabetic
rats at both 4 weeks (22.56 ± 3.51ng 2 h−1 versus 7.77 ±
0.93 ng 2 h−1, P < 0.001) and 12 weeks after the onset of
diabetes (25.01 ± 3.13 ng 2 h−1 versus 6.45 ± 1.09 ng 2 h−1,
P < 0.001). These levels were reduced significantly in diabetic
rats treated with 200mg kg−1 and 500mg kg−1 OPLE for 4
weeks to amounts that were not significantly diﬀerent from
that of nondiabetic rats (12.62 ± 1.31 ng 2 h−1 and 12.40 ±
1.93 ng 2 h−1, resp.). In contrast, only the higher dose of
OPLE (500mg kg−1) reduced the 8-OHdG level significantly
in 12-week diabetic rats compared to untreated diabetic rats
(15.02±2.31 ng 2 h−1, P < 0.01). These findings indicate that
antioxidant treatment with OPLE ameliorates the oxidative
stress-induced DNA damage in the kidney in the early stage
of experimental diabetes.
3.4.2. Lipid Peroxides (LPO). Renal cortical LPO were sig-
nificantly higher in diabetic rats than in nondiabetic rats
(Figure 2) at both 4 weeks (3.88 ± 0.15nmolsmg−1 protein
versus 2.48 ± 0.14 nmolsmg−1 protein, P < 0.001) and
12 weeks (6.08 ± 0.53 nmolsmg−1 protein versus 2.88 ±
0.17 nmolsmg−1 protein, P < 0.001) after induction of
diabetes. While 200mg kg−1 OPLE did not aﬀect renal
cortical LPO levels in 4-week and 12-week diabetic rats,
500mg kg−1 reduced significantly renal cortical LPO levels in
diabetic rats at both 4 weeks (2.97±0.17 nmols mg−1 protein,
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Figure 1: Eﬀect of OPLE on urinary 8-OHdG concentration. Data
are expressed as mean ± SEM (n = 6 per group). aP < 0.05; aaP <
0.01; aaaP < 0.001 versus corresponding nondiabetic; bP < 0.05;
bbP < 0.01 versus corresponding diabetes control.
P < 0.001) and 12 weeks (4.12 ± 0.39 nmolsmg−1 protein,
P < 0.05).
3.4.3. Glutathione (GSH). GSH constitute part of the en-
dogenous antioxidant defence system, the GSH redox cycle
plays a major role in scavenging hydrogen peroxide (H2O2)
under physiological conditions. To establish the eﬀect of
OPLE on endogenous antioxidant defence system in dia-
betes, we measured renal GSH content. As demonstrated
in (Figure 3), STZ-induced diabetes reduction in renal
cortical GSH content was improved by 500mg kg−1 OPLE
6 Evidence-Based Complementary and Alternative Medicine
No
nd
iab
eti
c
Di
ab
eti
c c
on
tro
l
Di
ab
eti
c +
OP
LE
 20
0 m
g k
g
−1
Di
ab
eti
c +
OP
LE
 50
0 m
g k
g
−1
0
2
4
6
8
R
en
al
 c
or
te
x 
LP
O
 (
n
m
ol
s 
m
g−
1
pr
ot
ei
n
)
aaa
aaa
bbb
4 weeks
(a)
No
nd
iab
eti
c
Di
ab
eti
c c
on
tro
l
Di
ab
eti
c +
OP
LE
 20
0 m
g k
g
−1
Di
ab
eti
c +
OP
LE
 50
0 m
g k
g
−1
0
2
4
6
8
R
en
al
 c
or
te
x 
LP
O
 (
n
m
ol
s 
m
g−
1
pr
ot
ei
n
)
aaa
b
12 weeks
(b)
Figure 2: Eﬀect of OPLE on renal cortical LPO concentration. Data
are expressed as mean ± SEM (n = 6 per group). aaaP < 0.001
versus corresponding nondiabetic; bP < 0.05, bbbP < 0.001 versus
corresponding diabetes control.
and not by 200mg kg−1 OPLE in diabetic rats at both
4 weeks (4.02 ± 0.16 nmolsmg−1 protein versus 2.98 ±
0.13 nmolsmg−1 protein in untreated diabetic rats, P <
0.05) and 12 weeks (4.13 ± 0.19 nmolsmg−1 protein versus
2.65 ± 0.36 nmolsmg−1 protein in untreated diabetic rats,
P < 0.05).
3.5. Transforming Growth Factor Beta-1 (TGF-β1). TGF-β1,
a fibrogenic cytokine, is purported to be a major mediator
of the hypertrophic changes in diabetic kidney disease. Thus
in accord with renal dysfunction and the increased markers
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Figure 3: Eﬀect of OPLE on kidney (renal cortex) GSH concen-
tration. Data are expressed as mean ± SEM (n = 6 per group).
aaP < 0.01 versus corresponding nondiabetic; bP < 0.05 versus
corresponding diabetes control.
of oxidative stress (urinary 8-OHdG excretion and renal
cortical LPO), significant higher concentrations of TGF-β1
were detected in plasma of diabetic rats in our study than
in nondiabetic rats (Figure 4) at both 4 weeks (17.09 ±
1.10 pgmL−1 versus 12.09 ± 0.75 pgmL−1, P < 0.01) and
12 weeks (21.34± 1.27 pgmL−1 versus 13.71± 0.81 pgmL−1,
P < 0.001). Treatment of diabetic rats with OPLE at both
concentrations for 4 weeks normalised plasma TGF-β1 con-
centrations (12.65± 1.12 pgmL−1 and 11.90± 0.56 pgmL−1
with 200mg kg−1 OPLE and 500mg kg−1 OPLE, respectively;
P < 0.05 and P < 0.01, resp.). OPLE at 200mg kg−1 did
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Figure 4: Plasma TGF-β1 concentration. Data are expressed as
mean ± SEM (n = 6 per group). aP < 0.05; aaP < 0.01; aaaP < 0.001
versus corresponding nondiabetic; bP < 0.05; bbP < 0.01 versus
corresponding diabetes control.
not have significant eﬀect on plasma TGF-β1 concentrations
in diabetic rats at 12 weeks but OPLE at 500mg kg−1
normalised the plasma TGF-β1 concentrations (16.01 ±
0.33 pgmL−1, P < 0.001).
3.6. Renal Histology. Figure 5 shows histological obser-
vations of kidney sections stained with PAS and Mas-
son’s trichrome. PAS-stained sections of the renal cortex
12 weeks after diabetes induction (Figure 5(b)) exhibited
marked glomerulosclerosis, characterized by glomerular
basement membrane thickening and mesangial expansion
with glomerular hypertrophy, compared with nondiabetic
controls. Remarkably, treatment with OPLE at both doses
(200mg kg−1 and 500mg kg−1) reduced glomerulosclerosis
and attenuated the mesangial matrix accumulation in the
diabetic group. Morphometric analysis revealed a significant
decrease in the mesangial area in OPLE-treated rats and the
data clearly demonstrates that OPLE treatment alleviated
the mesangial expansion (P < 0.05, Table 3). Masson’s
trichrome-stained section of diabetic kidney on week 4
exhibited increased collagen deposition, tubular dilation,
and degeneration of cortical tubules (Figure 5(c)) whilst
these changes were not apparent in the nondiabetic kidney.
In diabetic rats treated with OPLE, there was very little
collagen within the interstitium and no apparent tubular
pathology. Marked tubulointerstitial fibrosis characterized
by accumulation of extracellular matrix (ECM) protein in
cortex and medulla was observed in diabetic kidney on week
12 (Figure 5(d)). There was capillary occlusion, increased
proliferation of interstitial fibroblasts, tubular dilatation,
and atrophy whereas no apparent changes were detected
in kidney of nondiabetic control. Treatment with OPLE
reduced tubulointerstitial fibrosis in the renal cortex in the
diabetic group when compared to diabetic control (P < 0.05,
Table 3).
4. Discussion
It is well established that chronic hyperglycaemia is the main
determinant in the development and progression of DN, and
enhanced oxidative stress has been considered to contribute
to the pathological processes of diabetic renal complication
[11]. In the diabetic kidney, ROS is generated by several
pathways that include glycolysis, polyol pathway flux, uncou-
pling of nitric oxide synthase (NOS), xanthine oxidase,
NAD(P)H oxidase, and advanced glycation. Clinical studies
have demonstrated that strict control of hyperglycaemia can
reduce the occurrence or progression of DN; however, this
is extremely diﬃcult to maintain [2–5]. Therefore, the use
of alternate therapies that specifically target oxidative stress
implicated in diabetic microvascular complication may be
advantageous in addition to a strict glucose control.
The present study investigated the renoprotective eﬀect
of OPLE in experimental diabetes. OPLE is rich in catechins
[27, 28], and these polyphenolic compounds are considered
to have antioxidant capacity that is several folds higher than
that of vitamins C and E [28]. The results of this study
provide evidence that OPLE treatment introduced 72 h after
diabetes induction and maintained for 4 and 12 weeks,
prevented the diabetes-induced renal dysfunction as well as
kidney structural injury in diabetic rat. We hypothesised
that OPLE may retard renal dysfunction and renal pathology
associated with early DN in the STZ-induced diabetic rat, in
part, through attenuation of oxidative stress in the kidney,
in view of the fact that OPLE suppressed the elevation of
oxidative stress markers (8-OHdG, LPO), and improved
antioxidant defences as evidenced by increased levels of GSH.
In contrast to earlier study [21], these beneficial eﬀects of
OPLE could not be ascribed to improvement of the diabetic
condition because blood glucose levels were unaﬀected.
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Figure 5: Photomicrographs of kidneys stained with periodic acid-Schiﬀ (PAS) and Masson’s trichrome. Nondiabetic (A); diabetic control
(B); diabetic + OPLE 200mg kg−1(C); diabetic + OPLE 500mg kg−1(D). Bar = 50 μm.
Table 3: Eﬀects of OPLE on renal structure.
Nondiabetic Diabetic control
Diabetic + OPLE Diabetic + OPLE
200mg kg−1 500mg kg−1
(4 week) (4 week) (4 week) (4 week)
(12 week) (12 week) (12 week) (12 week)
Glomerulosclerotic index
0.23 ± 0.03 1.14 ± 0.06aa 0.89 ± 0.07aa 0.79 ± 0.5aa,b
0.34 ± 0.03 1.36 ± 0.04aa 0.93 ± 0.05aa,b 0.88 ± 0.04aa,b
Tubulointerstitial fibrosis index
0.49 ± 0.05 2.48 ± 0.18aa 1.48 ± 0.06a,b 1.16 ± 0.03b
0.61 ± 0.06 2.75 ± 0.16a 1.31 ± 0.23b 1.05 ± 0.14b
Data are expressed as mean± SEM of six experiments for each group. aP < 0.05,aaP < 0.01 versus corresponding nondiabetic; bP < 0.05 versus corresponding
diabetic control.
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We tested two diﬀerent doses of OPLE (200mg kg−1 and
500mg kg−1) to study the eﬀectiveness of this extract in
abrogating DN in short-term (4 weeks) and relatively longer-
term (12 weeks) diabetes. Both the doses of OPLE pro-
duced optimal eﬀects on oxidative stress marker (8-OHdG)
and renal dysfunction in short-term diabetes; however, it
appeared that the lower dose in contrast to the higher dose
was relatively less eﬀective in the longer-term diabetes. This
is conceivable given that with progression of the disease, the
extent of oxidative stress and its attendant renal dysfunction
would be greater and hence would require a higher dose of
the extract to counteract.
The STZ-diabetic rats in our study displayed increased
renal perfusion and hyperfiltration which are features of
early diabetes in both humans and animal models of
diabetes. On the single-nephron level, diabetic hyperfiltra-
tion is the result of renal vasodilation predominantly of
the preglomerular or aﬀerent resistance vessels [29]. This
haemodynamic abnormality was suggested to be mediated
by an increase in nitric oxide (NO) due to increased
glomerular expression of endothelial constitutive nitric oxide
synthase [30, 31]. On the contrary, altered arachidonic acid
metabolism has been linked to diabetic hyperfiltration; it
was proven that cyclooxygenase (COX)-2 expression was
increased in STZ-diabetic rats and inhibition of this enzyme
reversed the hyperfiltration in diabetic rats without altering
GFR in normal rats [32]. Later studies implicated oxidant
peroxynitrite (ONOO−) as a stimulus for upregulation
of COX-2 in diabetes [33, 34]. Consistent with earlier
interventional studies that used antioxidant vitamins in
STZ-diabetic rat [35, 36]; the current results demonstrated
that hyperfiltration was blunted by OPLE to control values.
The mechanism by which OPLE improved hyperfiltration
however remains to be researched. A natural antioxidant
was reported to reduce 3-nitrotyrosine proteins, a marker
of ONOO− production, in renal tissue of STZ-diabetic rat
[37]. While this is conjectural, we proposed that OPLE
ameliorated hyperfiltration probably due to its antioxidant
property that limits the generation or activity of ONOO−
and in consequence prevents upregulation of COX-2 and
reduces formation of vasodilatory prostanoids.
Proteinuria, a marker of DN is an important risk factor
for progressive renal impairment. We therefore assessed
the eﬀect of OPLE on urinary protein excretion to fur-
ther evaluate the renal protective eﬀect of this extract.
Hyperfiltration and alteration in glomerular filtration barrier
(alterations in endothelium with its glycocalyx, glomerular
basement membrane, and podocyte function) contribute to
proteinuria in diabetes mellitus. ROS is believed to be one of
the key players involved in the pathogenic pathways that lead
to glomerular filtration barrier damage. Glomerular ROS
production was increased in experimental diabetes [38] and
podocytes produced ROS in response to high glucose [39].
ROS has been shown to directly decrease heparan sulphate
proteoglycans production within the glycocalyx [40], disrupt
the endothelial glycocalyx [41] and was implicated in early
podocyte damage and apoptosis [39]. On the contrary,
transgenic overexpression of superoxide dismutase attenu-
ated renal injury, including increases in albumin excretion
rate [42] and antioxidant therapies potentially prevented
podocyte damage in early DN [43, 44]. In our present study,
diabetic rats developed proteinuria by 4 weeks, and OPLE
had a positive eﬀect on this parameter. These results may
indicate that OPLE can attenuate renal damage in diabetic
rats. Moreover, known antioxidants such as polyphenols and
catechins are biological active components of OPLE, and
these compounds were found to improve proteinuria in
diabetes-induced oxidative stress [21, 45].
STZ-diabetic rat manifested renal hypertrophy in the
present study and OPLE reduced the renal enlargement
although this eﬀect was not significant. Experimental studies
suggested that amelioration of oxidative stress by catechin
and other antioxidants abrogated renal enlargement in DN
[42, 46, 47]. Pathologic hallmarks of early DN include
increased glomerular basement membrane thickness and
mesangial expansion, and these features are in concordant
with our present results. In conjunction with these ultra-
structural changes, our present study demonstrated elevation
in plasma TGF-β1 levels in STZ-diabetic rats. Expansion
of the mesangial matrix and thickening of the glomerular
basementmembrane in DN as a result of excessive deposition
of ECM proteins may be due to upregulation of TGF-β1
and other growth factors [48]. It is well established that
hyperglycaemia-induced ROS activate signal transduction
mechanisms and transcription factors and upregulate TGF-
β1 and ECM genes and proteins [15]. Treatment of diabetic
rats with OPLE preserved renal architecture and this was
conceivably reflected in suppression of the increases in
plasma TGF-β1 levels. In corroboration with our findings,
antioxidants significantly inhibit high glucose- and H2O2-
induced TGF-β1 and fibronectin (glomerular matrix pro-
tein) upregulation [49–53].
Quantification of ROS would provide direct evidence
of the involvement of oxidative stress in diabetic kidney
[46, 54, 55]. Although we did not measure ROS directly,
several line of evidence suggested that lipid peroxidation and
formation of 8-OHdG constituted a condition of increased
oxidative stress [56–58]. Our present findings of increased
LPO, 8-OHdG in parallel with compromised concentration
of the nonenzymatic antioxidant GSH in diabetic kidney
clearly suggested that enhanced oxidative stress was present
at an early stage of diabetes. The suggestion that renal
oxidative stress in STZ-diabetic rats was a consequence
of hyperglycaemia rather than well-established prooxidant
eﬀect of STZ itself was supported by findings which demon-
strated correction of impaired antioxidative defense and
DNA oxidative damage in the diabetic kidney after insulin
administration to animals with established STZ-induced
diabetes [59, 60]. The diabetes-induced changes in oxidative
markers (LPO, 8-OHdG, GSH) in our present study were
partially or completely prevented by OPLE, and this is quite
consistent with the eﬀect of this compound in other tissues
of diabetic animals [21] as well as in other nondiabetic
models of oxidative stress [27, 28]. These results indicate
that increased oxidative stress which was present in diabetic
kidney may be counteracted by OPLE.
This study indicates that catechins-rich OPLE can mod-
ulate oxidative stress caused by hyperglycaemic-induced
10 Evidence-Based Complementary and Alternative Medicine
generation of free radicals in diabetic kidney as well as
preventing renal dysfunction and structural injury. DN
is a major cause of end-stage renal disease, and it is
initially characterised by glomerular hemodynamic abnor-
malities that result in glomerular hyperfiltration, leading
to glomerular damage as evidenced by microalbuminuria.
The main advantage of OPLE was that it could ameliorate
both hyperfiltration and proteinuria unlike other antioxidant
vitamins. Furthermore, renal protection by OPLE in DN
depends on the dose of the extract relative to body weight
as well as progression of the disease implying that the dose
given should correspond to the degree of in vivo oxidative
stress within the kidney.
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